Efficacy and safety of blinatumomab combination therapy in high‑risk B‑cell acute lymphoblastic leukemia: A systematic review and meta‑analysis

Wang,Mei; Yu,Xinlin; Zou,Zhongqing; He,Yan; Chen,Lvlin; Lan,Ying

doi:10.3892/ol.2026.15552

May-2026 Volume 31 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2026 Volume 31 Issue 5

Full Size Image

Article Open Access

Efficacy and safety of blinatumomab combination therapy in high‑risk B‑cell acute lymphoblastic leukemia: A systematic review and meta‑analysis

Authors:
- Mei Wang
- Xinlin Yu
- Zhongqing Zou
- Yan He
- Lvlin Chen
- Ying Lan
View Affiliations / Copyright

Affiliations: Department of Hematology, Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610000, P.R. China, Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Hematology, Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610000, P.R. China, Department of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610000, P.R. China, Department of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610000, P.R. China

Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 197
|
Published online on: March 26, 2026

https://doi.org/10.3892/ol.2026.15552
Expand metrics +

Abstract

The present study aimed to evaluate the efficacy and safety of blinatumomab‑based combination therapy for high‑risk B‑cell acute lymphoblastic leukemia (B‑ALL). PubMed, Embase, Web of Science and the Cochrane Library were searched for clinical studies on blinatumomab. The primary endpoints were complete remission (CR), minimal residual disease (MRD) and complete molecular remission (CMR). The secondary endpoint was overall survival (OS). Safety outcomes included adverse events (AEs), cytokine release syndrome, neurological events and hematological toxicity. A total of 11 studies involving 402 patients were included. The pooled CR rate was 87% (95% CI, 78‑95%), the MRD negativity rate was 81% (95% CI, 75‑87%) and the CMR rate was 81% (95% CI, 69‑92%). The 1‑year OS rate was 91% (95% CI, 78‑100%), the 2‑year OS rate was 87% (95% CI, 71‑100%) and the 3‑year OS rate was 52% (95% CI, 36‑66%). Regarding safety, 86% (95% CI, 77‑96%) of patients experienced all‑grade AEs. Grade ≥3 AEs were generally consistent with known safety profiles, with the most common events being neutropenia (38%; 95% CI, 0‑84%), febrile neutropenia (26%; 95% CI, 10‑43%), and hyperglycemia (21%; 95% CI, 5‑36%). In conclusion, blinatumomab‑based combination therapy is an effective treatment for high‑risk B‑ALL with manageable toxicity.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Efficacy and safety of blinatumomab combination therapy in high‑risk B‑cell acute lymphoblastic leukemia: A systematic review and meta‑analysis

This article is mentioned in:

Abstract

Related Articles